GGrantIndex
← Leaderboards

Arya Biragyn

Aging

Google Scholar ↗PubMed ↗ORCID ↗
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding mix

By agency

—

By mechanism

—

Top collaborators

No co-investigators on record.

Most similar at Aging

Same institution · by research overlap

Others in their field

Top investigators on “Cells”

Research focus

CellsImmuneB-LymphocytesAlzheimer&AposReportingAntibodiesResponseNeoplasm MetastasisMediatingMalignant NeoplasmsImmune ResponseVaccinesMalignant Breast NeoplasmT-LymphocyteAgingGenerationsPublishingPublicationsPathway InteractionsTumorReceptorS DiseaseLinkImmunology

Grant awards (52)

Immunology of aging and immunotherapy of aging-associated diseases$807,712
ZIA · FY2025 · AG · contact PI
ALZHEIMERS RESEARCH PROJECT: B cells promote Alzheimers disease via cytolytic CD8+ T cells$158,970
ZIA · FY2025 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$867,489
ZIA · FY2024 · AG · contact PI
ALZHEIMERS RESEARCH PROJECT: B cells promote Alzheimers disease via cytolytic CD8+ T cells$360,948
ZIA · FY2024 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$979,308
ZIA · FY2023 · AG · contact PI
Manifestation of Alzheimer's Disease requires B cells$447,017
ZIA · FY2023 · AG · contact PI
B cells promote Alzheimers disease via cytolytic CD8+ T cells$447,017
ZIA · FY2023 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$1,226,456
ZIA · FY2022 · AG · contact PI
The origin of tBregs and their trans-differentiation in cancer$1,226,456
ZIA · FY2022 · AG · contact PI
B cell-immunoglobulin axis to explain aging onset of Alzheimer's Disease$44,681
ZIA · FY2022 · AG · contact PI
B cells promote Alzheimers disease via cytolytic CD8+ T cells$33,511
ZIA · FY2022 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$1,576,243
ZIA · FY2021 · AG · contact PI
The origin of tBregs and their trans-differentiation in cancer$1,576,243
ZIA · FY2021 · AG · contact PI
Development of simpler immunotheraputics$630,497
ZIA · FY2021 · AG · contact PI
The role of immune cells in Alzheimer's disease$356,020
ZIA · FY2021 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$1,971,370
ZIA · FY2020 · AG · contact PI
The origin of tBregs and their trans-differentiation in cancer$1,596,810
ZIA · FY2020 · AG · contact PI
Development of simple formulations for vaccine use$1,577,096
ZIA · FY2020 · AG · contact PI
The role of immune cells in Alzheimer's disease$528,921
ZIA · FY2020 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$637,389
ZIA · FY2019 · AG · contact PI
Regulatory immune cells in immune suppression: The role of tBregs$637,389
ZIA · FY2019 · AG · contact PI
The role of immune cells in Alzheimer's disease$540,952
ZIA · FY2019 · AG · contact PI
Regulatory immune cells in immune suppression: The role of tBregs$503,916
ZIA · FY2018 · AG · contact PI
The role of immune cells in Alzheimer's disease$411,503
ZIA · FY2018 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$370,353
ZIA · FY2018 · AG · contact PI
The role of immune cells in Alzheimer's disease$778,844
ZIA · FY2017 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$588,623
ZIA · FY2017 · AG · contact PI
Regulatory immune cells in immune suppression: The role of tBregs$470,899
ZIA · FY2017 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$889,306
ZIA · FY2014 · AG · contact PI
Development of therapeutic chemokine-based formulations$754,563
ZIA · FY2014 · AG · contact PI
Regulatory immune cells in immune suppression: The role of tBregs$485,076
ZIA · FY2014 · AG · contact PI
Immunology of aging and immunotherapy of aging-associated diseases$628,091
ZIA · FY2013 · AG · contact PI
Development of therapeutic chemokine-based formulations$342,595
ZIA · FY2013 · AG · contact PI
Regulatory immune cells in immune suppression: The role of tBregs$171,298
ZIA · FY2013 · AG · contact PI
Development of therapeutic chemokine-based formulations$255,323
ZIA · FY2012 · AG · contact PI
Novel immunotherapeutic strategies to treat cancer and diseases of old people$212,770
ZIA · FY2012 · AG · contact PI
Regulatory immune cells in immune suppression: The role of tBregs$127,662
ZIA · FY2012 · AG · contact PI
Development of therapeutic chemokine-based formulations$377,262
ZIA · FY2011 · AG · contact PI
Inflammation and Immunotherapy: Vaccines to treat cancer and Alzheimer's disease$262,064
ZIA · FY2011 · AG · contact PI
Regulatory immune cells in immune suppression and metastasis$244,387
ZIA · FY2011 · AG · contact PI
Development of therapeutic chemokine-based formulations$273,688
ZIA · FY2010 · AG · contact PI
The role of immunosuppressive cells in metastasis$210,529
ZIA · FY2010 · AG · contact PI
Chemoattractant-based immunotherapeutics to modulate immune and cancer cells$200,003
ZIA · FY2010 · AG · contact PI
Development of therapeutic chemokine-based formulations$251,405
ZIA · FY2009 · AG · contact PI
Chemoattractant-based immunotherapeutics to modulate immune and cancer cells$183,719
ZIA · FY2009 · AG · contact PI
The role of immunosuppressive cells in metastasis$174,050
ZIA · FY2009 · AG · contact PI
Development of therapeutic chemokine-based formulations$265,411
Z01 · FY2008 · AG · contact PI
The role of immunosuppressive cells in metastasis$237,955
Z01 · FY2008 · AG · contact PI
Chemoattractant-based immunotherapeutics to modulate immune and cancer cells$214,480
Z01 · FY2008 · AG · contact PI
Chemoattractant-based vaccines which modulate APCs$0
Z01 · FY2006 · AG · contact PI
Chemoattractant-based vaccines which modulate APCs$0
Z01 · FY2005 · AG
Chemoattractant-based vaccines which modulate APCs$0
Z01 · FY2004 · AG